FIA
BHVN

FNY Investment Advisers’s Biohaven Pharmaceutical Holding Company Ltd. BHVN Stock Holding History

FNY Investment Advisers’s Portfolio BHVN Stock Details BHVN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-2,300
Closed -$34K – 1635
2025
Q3 		$34K Hold
2,300
– – 0.01% 587
2025
Q2 		$32K Buy
2,300
+1,500
+188% +$20.9K 0.01% 494
2025
Q1 		$19K Buy
+800
New +$19K 0.01% 415
2023
Q1 		– Sell
-250
Closed -$3K – 856
2022
Q4 		$3K Sell
250
-263,322
-100% -$40M ﹤0.01% 408
2022
Q3 		$1.66M Buy
263,572
+253,692
+2,568% +$37.6M 1.15% 22
2022
Q2 		$1.44M Buy
+9,880
New +$1.26M 1.06% 25
2019
Q3 		– Sell
-22,600
Closed -$989K – 1358
2019
Q2 		$989K Buy
+22,600
New +$1.27M 0.29% 44

Other funds holding BHVN

KCM
Knoll Capital Management Miami, Florida $180M AUM 66.11% 1-Year Est. Return
BC
Birchview Capital Burlington, Vermont $176M AUM 95.04% 1-Year Est. Return

FNY Investment Advisers's BHVN Position: Q4 2025 in Review

FNY Investment Advisers sold out of Biohaven Pharmaceutical Holding Company Ltd. (BHVN) in Q4 2025, closing a stake of 2,300 shares — an estimated $34K sold.

FNY Investment Advisers first reported a position in BHVN in Q2 2019 and held it in 7 quarters. The position peaked at $1.66M in Q3 2022. 2 funds tracked by Wall St. Rank hold BHVN as of Q4 2025.

  • FNY Investment Advisers reported no remaining Biohaven Pharmaceutical Holding Company Ltd. position as of Q4 2025 after selling out during the quarter.
  • FNY Investment Advisers sold 2,300 Biohaven Pharmaceutical Holding Company Ltd. shares in Q4 2025, an estimated $34K.
  • FNY Investment Advisers first reported a position in Biohaven Pharmaceutical Holding Company Ltd. in Q2 2019 and held it in 7 quarters.
  • FNY Investment Advisers's Biohaven Pharmaceutical Holding Company Ltd. position peaked at $1.66M in Q3 2022.
  • 2 funds tracked by Wall St. Rank held Biohaven Pharmaceutical Holding Company Ltd. as of Q4 2025.

Based on FNY Investment Advisers's 13F filing for Q4 2025, filed 16 Jan 2026.